Kurse werden geladen...
Prognose
Das durchschnittliche Kursziel der Analysten beträgt 1,75€(−24,89%). Der Median liegt bei 1,75€(−24,89%).
Kaufen | 4 |
Halten | 0 |
Verkaufen | 0 |
Scoring-Modelle
Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.
News
NRx Pharmaceuticals, Inc. (NRXP) Q1 2025 Earnings Call Transcript
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP ) Q1 2025 Earnings Conference Call May 15, 2025 4:30 PM ET Company Participants Matthew Duffy – Chief Business Officer Jonathan Javitt – Founder, Chairman, and Chief Executive Officer Michael Abrams – Chief Financial Officer Conference Call Participants Tom Shrader – BTIG Ed Woo – Ascendiant Capital Operator Good afternoon, ladies and gentlemen, and welcome to the NRx Pharmaceuticals First Quarter 2025 Earnings Call. At this time, all lines are in a listen-only mode.» Mehr auf seekingalpha.com
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports First Quarter 2025 Financial Results and Provides Corporate Update
Company has continued to advance its previously announced plan to obtain FDA approval for two new drugs and to develop a network of clinics focused on neuroplastic therapies to treat severe and suicidal depression, PTSD, and related conditions. Clinic acquisition financing is at the HOPE Therapeutics level and non-dilutive to NRXP shareholders In January 2025 completed the third tranche of a convertible note offering and registered direct equity offering to an institutional investor on favorable terms to the Company; expected to provide sufficient cash to support operations through the end of 2025.» Mehr auf prnewswire.com
HOPE Therapeutics, Inc. a subsidiary of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Signing of Term Sheet for $7.8 Million Debt Financing to Fuel HOPE Clinic Acquisitions
Term sheet with Universal Capital, LLC to fund HOPE Therapeutics clinic acquisition strategy Funding tied to already-announced acquisitions, with additional tranches contemplated for further growth, subject to standard due diligence Together with previously announced term sheet with a strategic investor, HOPE funding of $10.3 million is planned in the near term MIAMI , May 15, 2025 /PRNewswire/ -- HOPE Therapeutics™, Inc. ("HOPE"), a multi-site clinical care delivery organization and wholly-owned subsidiary of NRx Pharmaceuticals, Inc. (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, today announced signing of a term sheet with Universal Capital, LLC ("Universal") to provide $7.8 million in acquisition capital to initiate HOPE's planned national rollup of interventional psychiatry clinics, commencing with previously-announced acquisitions of Dura Medical, Kadima, and NeuroSpa. Together with proceeds of a previously announced strategic investment, this financing is anticipated to provide $10.3 million in acquisition capital.» Mehr auf prnewswire.com
Unternehmenszahlen
(EUR) | März 2025 | |
---|---|---|
Umsatz | 0,00 | - |
Bruttoeinkommen | 0,00 | 100,00% |
Nettoeinkommen | −5,10 Mio | 15,77% |
EBITDA | −5,10 Mio | 12,68% |
Fundamentaldaten
Metrik | Wert |
---|---|
Marktkapitalisierung | 39,99 Mio€ |
Anzahl Aktien | 17,29 Mio |
52 Wochen-Hoch/Tief | 5,27€ - 0,96€ |
Dividenden | Nein |
Beta | 1,45 |
KGV (PE Ratio) | −1,80 |
KGWV (PEG Ratio) | −0,11 |
KBV (PB Ratio) | −1,72 |
KUV (PS Ratio) | 11.410,87 |
Unternehmensprofil
Name | NRX Pharmaceuticals Inc. |
CEO | Dr. Jonathan C. Javitt M.D., M.P.H. |
Mitarbeiter | 2 |
Assets entdecken
Shareholder von NRX Pharmaceuticals Inc. investieren auch in folgende Assets